Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Nabriva Therape Ads (NBRV)

Nabriva Therape Ads (NBRV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 586,919
  • Shares Outstanding, K 497,389
  • Annual Sales, $ 5,030 K
  • Annual Income, $ -69,480 K
  • 60-Month Beta 1.84
  • Price/Sales 119.72
  • Price/Cash Flow N/A
  • Price/Book 7.98
Trade NBRV with:

Options Overview Details

View History
  • Implied Volatility 226.66%
  • Historical Volatility 47.33%
  • IV Percentile 49%
  • IV Rank 24.64%
  • IV High 775.71% on 07/19/21
  • IV Low 47.11% on 07/30/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 207
  • Volume Avg (30-Day) 120
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 10,289
  • Open Int (30-Day) 8,828

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.23
  • Number of Estimates 3
  • High Estimate -0.21
  • Low Estimate -0.26
  • Prior Year 0.90
  • Growth Rate Est. (year over year) -125.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0300 +14.56%
on 08/27/21
1.2300 -4.07%
on 09/23/21
+0.1200 (+11.32%)
since 08/24/21
3-Month
1.0000 +18.00%
on 08/19/21
1.4100 -16.31%
on 06/28/21
-0.2000 (-14.49%)
since 06/24/21
52-Week
1.0000 +18.00%
on 08/19/21
6.1880 -80.93%
on 10/12/20
-4.1200 (-77.74%)
since 09/24/20

Most Recent Stories

More News
Nabriva Therapeutics to Present Data at IDWeek 2021

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced data...

NBRV : 1.1800 (-2.48%)
Nabriva and Vizient Enter into Agreement to Make XENLETA(R) (lefamulin) Available to Vizient's Pharmacy Network Program

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it...

NBRV : 1.1800 (-2.48%)
Lefamulin Receives Approval in Taiwan for Treatment of Community-Acquired Pneumonia

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that...

NBRV : 1.1800 (-2.48%)
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that...

NBRV : 1.1800 (-2.48%)
Nabriva Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that...

NBRV : 1.1800 (-2.48%)
Nabriva Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

-Revenues of $8.2 million driven by launch of own National Drug Code (NDC) for SIVEXTRO-

NBRV : 1.1800 (-2.48%)
Acurx Pharmaceuticals Joins the Antimicrobials Working Group

/PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (Acurx) to its coalition of companies with the mission to combat drug...

CDTX : 2.24 (-2.61%)
ITRM : 0.5384 (-3.53%)
NBRV : 1.1800 (-2.48%)
PRTK : 5.29 (+8.18%)
SCYX : 5.58 (-0.36%)
SMMT : 5.22 (-2.97%)
ACXP : 4.39 (-7.68%)
Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase

Dr. Reddy's (RDY) earnings decline while sales grow year over year in first-quarter fiscal 2022.

RDY : 64.87 (-0.28%)
RGEN : 323.26 (-0.29%)
CORT : 20.29 (-0.98%)
NBRV : 1.1800 (-2.48%)
Nabriva Therapeutics to Report Second Quarter 2021 Financial Results and Recent Corporate Highlights on August 5, 2021

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that...

NBRV : 1.1800 (-2.48%)
Down 15.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Nabriva Therapeutics AG (NBRV)

Nabriva Therapeutics AG (NBRV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings...

NBRV : 1.1800 (-2.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins,...

See More

Key Turning Points

3rd Resistance Point 1.2567
2nd Resistance Point 1.2333
1st Resistance Point 1.2067
Last Price 1.1800
1st Support Level 1.1567
2nd Support Level 1.1333
3rd Support Level 1.1067

See More

52-Week High 6.1880
Fibonacci 61.8% 4.2062
Fibonacci 50% 3.5940
Fibonacci 38.2% 2.9818
Last Price 1.1800
52-Week Low 1.0000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar